Phase 1 N=124 Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke
Stroke
Primary: Change in Arm Motor Fugl-Meyer Score From Baseline to 30 Days Post-therapy — 7.86; 8.36 units on a scale — p=.96
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=53 The Effect of Physical Training and the Omega 3 Consumption on Attention Deficit Hyperactivity Disorder in Children
Attention Deficit Hyperactivity Disorder
Primary: Conners Scale — 36.64; 42.31; 40.08; 36.82 units on a scale — p=0.05
Phase 2 N=47 Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)
Eosinophilic Esophagitis
Primary: Absolute Change From Baseline in Straumann Dysphagia Instrument (SDI) Patient Reported Outcome (PRO) Total Score at Week 10 — -1.3; -3.0 Score on a Scale — p=0.0304
N/A N=8 Low Intensity Blood Flow Restriction Training Study
Muscle Mass
Primary: One Repetition Maximum — 302.9 pounds
Phase 2 N=36 Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)
Chronic Lymphocytic Leukemia
Primary: Rate of Complete Remission/Complete Remission With Incomplete Recovery of the Bone Marrow (CR/CRi), as Assessed by Investigator Using Modified International Workshop on…
N/A N=181 Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis
MRSA Infections
Primary: Overall Number of Participants With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections. — 2; 0; 4 participants
N/A N=69 Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Neuroblastoma
Primary: Therapeutic Response — 40; 3; 1; 6 Participants
Phase 3 N=273 Beraprost-314d Added-on to Tyvaso® (BEAT)
Pulmonary Arterial Hypertension
Primary: Number of Participants That Experienced Clinical Worsening — 8; 13; 23; 14 Participants
N/A N=200 PICO Breast Reduction Clinical Study Looking at Incision Healing Complications
Delayed Healing
Primary: Number of Participants Experiencing Incision Healing Complications up to Day 21 Postoperatively — 113; 86; 123; 76 participants
Phase 1 N=60 Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169
Healthy Subjects
Primary: Number of Adverse Events — 9; 4; 5; 2 AEs
Phase 2 N=40 A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
Head and Neck Squamous Cell Carcinoma
Primary: Change in Immune Response After Tadalafil Administration
Phase 1 N=61 A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
Non-hematologic Malignancy
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 7; 6; 9; 11 Participants
Phase 3 N=111 Cocaine/Crack and Reduction of Compulsion With Biperiden
Cocaine Dependence
Primary: Compulsion — 5.9; 5.5 score on a scale — p=<0.05
Phase 3 N=478 Established Status Epilepticus Treatment Trial
Benzodiazepine Refractory Status Epilepticus
Primary: Number of Participants With Clinical Cessation of Status Epilepticus - Intention to Treat — 53; 56; 68 Participants
Phase 1 N=21 Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen
Vasomotor Symptoms (VMS)
Primary: Adverse Event (AE) Reporting of Q-122 — 7; 7 Participants